Cite
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
MLA
De Wit, Stéphane, et al. “Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.” Journal of Acquired Immune Deficiency Syndromes (1999), Mar. 2024. EBSCOhost, https://doi.org/10.1097/QAI.0000000000003395.
APA
De Wit, S., Bonnet, F., Osiyemi, O., Bisshop, F., Olalla, J., Routy, J.-P., Wyen, C., Moodley, R., Pappa, K., Wang, R., Oyee, J., Saggu, P., Letang, E., Wynne, B., Jones, B., Smith, K. Y., & Ait-Khaled, M. (2024). Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196. Journal of Acquired Immune Deficiency Syndromes (1999). https://doi.org/10.1097/QAI.0000000000003395
Chicago
De Wit, Stéphane, Fabrice Bonnet, Olayemi Osiyemi, Fiona Bisshop, Julian Olalla, Jean-Pierre Routy, Christoph Wyen, et al. 2024. “Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.” Journal of Acquired Immune Deficiency Syndromes (1999), March. doi:10.1097/QAI.0000000000003395.